Dr. Mehra is a senior drug developer at a leading pharmaceutical company in India, renowned for producing various medications, including lifesaving drugs critical for treating chronic and rare diseases. Since its inception, the company has emphasized the quality and affordability of its drugs. Recently, under revised government guidelines, pharmaceutical companies are required to market a finished product only after obtaining "satisfactory results" from tests on the ingredients. Additionally, they must retain a sufficient quantity of samples of both intermediate and final products to allow repeated testing or verification of a batch. Dr. Mehra's team is in the final stages of developing a new medication for a rare but life-threatening disease. This drug has shown promising results in clinical trials. However, there have been unresolved concerns about the long-term side effects of the drug, observed in a small percentage of trial subjects. Despite this, the company has not released any major drug in the past decade, leading to significant pressure from the board members to expedite the drug's release. (a) Identify the stakeholders in the above case study. (b) Discuss the ethical issues faced by Dr. Mehra. (c) Analyse the options available to Dr. Mehra in the above case. Which of these would you choose and why?
Ujjwal Priyank, AIR 10, 2025
The case study highlights the issue of efficiency and effectiveness in drug development, while maintaining required standards.
(b) Ethical issues faced by Dr. Mehra
1. Ensuring drug standard v/s meeting company deadlines 2. Personal gain v/s life of common citizens. 3. Accountability as a drug developer v/s responsibility as an employee.
(c) Options available to Dr. Mehra
(i) Continue with his discovery according to set standards.
| Pros | Cons | |---|---| | Ensure health and life of common people | Not good for profits of the pharmaceutical company. | | Responsibility as a doctor | |
(ii) May ignore the standards and launch the drug early.
| Pros | Cons | |---|---| | Profitable in the shorter run | May endanger the life of many. | | Boost to the reputation | Lack of integrity as a doctor. |
In my opinion, there should be no corruption in pharma sector for personal gains. Dr. Mehra must ensure that he remains accountable to the common citizens. Let the process take time but it must be safe!